Benzinga's Microcap Movers for Thursday June 7, 2012
Below are highlights from Benzinga's daily coverage of microcap securities making big moves:
Bio-Matrix Scientific Group
Shares of Bio-Matrix Scientific Group (BMSN), the the La Mesa, CA biotechnology company, rose 89.09% Thursday on 741 times the average daily volume.
Bio-Matrix Scientific Group announced Thursday that its wholly owned subsidiary Regen BioPharma, Inc. has executed an exclusive option agreement which grants Regen BioPharma an option to license Patent #6,821,513 which patents methods of stimulating blood production in patients with deficient stem cells. The patent, as well as data licensed with the patent, covers methods of stimulating the bone marrow to generate new blood cells. The patent and option agreement are disclosed in the Company's most recent 8K filed with the US Securities and Exchange Commission on June 6, 2012.
"The technology has broad applicability to help cancer patients recover faster following chemotherapy, as well as for recipients of bone marrow and cord blood transplants. Currently, new blood cell production is stimulated by expensive drugs such as Neupogen and Neulasta which replicate the body's growth factors but can cause side effects and rely upon the diminished recuperative powers of an immune compromised patient," stated J. Christopher Mizer, President of Regen BioPharma
Bio-Matrix Scientific Group closed at $0.01 on Thursday.
Shares of Revolutionary Concepts (REVO), the Charlotte, NC developer of smart camera technology, rose 200% Thursday on 34 times the average daily volume.
Revolutionary Concepts, acknowledges opportunistic developments for its wireless technology since the awarding of five additional patents from the U.S. Commerce Department's United States Patent and Trademark Office. The new patents appropriate RCI full ownership and use of the technology.
Ronald Carter, President of RCI, announces that, "Unlike the original patent that deals with the technology itself, the five additional patents address ownership of the method and use of the technology."
As RCI moves forward with its EyeTalk Communicator, Senior Vice President of Finance Solomon RC Ali discloses that the five additional patents are extremely beneficial to the future of the EyeTalk Communicator because it allots additional years where RCI is the only controller of the space for the technology's method and use. Revolutionary Concepts closed at $0.02 on Thursday.
Shares of Identive Group (NASDAQ: INVE), the Santa Ana, CA Secure ID company, rose 14.47% Thursday on 10 times the average daily volume.
Identive Group announced Thursday it is providing 266,000 smart card readers to a U.S. government agency for secure authentication and email encryption. The SCR3310/v2 readers fit easily into the USB port of a PC and allow government employees to quickly and securely log on to the agency's computer network.
"Cyber security is receiving an increasing amount of focus across industries and among consumers as well. Using smart cards to validate user identities is an important step in protecting the data on a computer and the assets in a network. U.S. government agencies are ahead of the curve in adopting smart card-based security and have a clear understanding of the benefits," explained Dr. Manfred Mueller, COO Identification Products for Identive. "For this agency, the product delivery schedule was quite aggressive and Identive was the only supplier capable of delivering the required volumes in a short time. Once again we have demonstrated why Identive is recognized as a trusted supplier to the U.S. government market."
Identive Group closed at $1.12 on Thursday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.